Drug-induced myopathies
- 1 October 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 13 (5) , 541-545
- https://doi.org/10.1097/00019052-200010000-00006
Abstract
Two major entities continue to be controversial in the field of clinical myotoxicity: the various myopathies that are induced by the cholesterol-lowering agents and the acute quadriplegic myopathy of intensive care. Both conditions are relatively common, but their pathogenesis is unclear. The problematic issues related to these disorders are presented, with suggested topics for future research.Keywords
This publication has 18 references indexed in Scilit:
- Prevention of coronary heart disease Part I. Primary preventionDisease-a-Month, 1999
- ACUTE QUADRIPLEGIC MYOPATHY WITH MYOSIN-DEFICIENT MUSCLE FIBRES AFTER LIVER TRANSPLANTATIONTransplantation, 1999
- Distribution of serum creatine kinase activity in young healthy personsClinica Chimica Acta; International Journal of Clinical Chemistry, 1999
- Drugs and toxins associated with myopathiesCurrent Opinion in Rheumatology, 1998
- Myopathy Induced by HMG–CoA Reductase Inhibitors in Rabbits: A Pathological, Electrophysiological, and Biochemical StudyToxicology and Applied Pharmacology, 1998
- Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agentsNeuromuscular Disorders, 1998
- Acute myopathy after liver transplantationNeurology, 1998
- TOXIC MYOPATHIESNeurologic Clinics, 1997
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988
- SEVERE MYOPATHY AFTER STATUS ASTHMATICUSThe Lancet, 1977